Crucell « Terug naar discussie overzicht

Crucell Channel

84 Posts, Pagina: 1 2 3 4 5 » | Laatste

Omlaag ↓

flosz 23 maart 2011 16:12

Crucell Channel
www.youtube.com/user/CrucellVideo

Working at Crucell
At Crucell we dream of a world free of infectious disease. In 2010, our vaccines prevented more than 3.6 million cases of infectious disease and over 809,000 deaths.
Are you looking for a job where you can make a real difference to global health? Come and join us!
www.crucell.com/Careers

www.youtube.com/watch?v=DkJPy96QhkE

Crucell corporate movie
www.youtube.com/watch?v=_vq-0K75_qg
************

BIT Life Sciences 3rd Annual World Vaccine Event
www.bitlifesciences.com/wcv2011/defau...
Bejing CN
Crucell's CSO, Dr Jaap Goudsmit will give a presentation entitled "Protective Immunity of vaccine efficacy: Lessons learned from West Nile"

12 april 2011 15:40 ()
World Congress Vaccine Washington 2011, Crucell sponsored event
www.terrapinn.com/conference/world-va...
Washington, DC US
Crucell's VP for Preclinical and Clinical Research, Dr Robert Friesen will give a presentation entitled: Novel human monclonal antibodies against group 1 and 2 Influenza A strains for prevention and treatment

8 mei 2011 12:53 ()
International Society of Travel Medicine, Crucell sponsored event
www.istm.org/
Boston US
From 08-12 May 2011

7 juni 2011 12:53 ()
29th Annual meeting for the European Society for Pediatric Infectious Disease, ESPID
www2.kenes.com/espid2011/Pages/Home.aspx
Hague NL
From 7-11 June 2011, off site Crucell sponsored event
***********

A peptide based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines.
www.ncbi.nlm.nih.gov/pubmed/21411600

Successful Memory Response Following an up to 11 Years Delayed Booster Dose with a Virosome-formulated Hepatitis A Vaccine (Epaxal(R)).
www.ncbi.nlm.nih.gov/pubmed/21411599
**********

Crucell ’s(a subsidiary of Johnson & Johnson) PER.C6 inside:

PAT-SM6 Disease Target, GRP78, Gains Growing Attention from Research Community www.patrys.com/images/stories/mediare...

Gastric Cancer Antibody Exceeds Manufacturing Yield Expectations; Disease Target of Industry Interest
www.patrys.com/images/stories/mediare...

PATRYS PRESENTS TO INVESTORS IN AUSTRALIA
AND ASIA
www.patrys.com/images/stories/mediare...
*********

Antwoord vragen Gesthuizen over persoonlijk belang commissarissen bij overname Crucell. ikregeer.nl/s/ah-103046
********

Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines
clinicaltrials.gov/ct2/show/NCT013074...
clinicaltrials.gov/ct2/results?term=C...
************

www.youtube.com/watch?v=PTTsyk-pyd8

Btw: Tomorrow is WorldTBDay!

Bijlage:

flosz 1 april 2011 11:19

Adimmune to Kick Off Human-Vaccine Exports This Year
Taipei, March 31, 2011 (CENS)--Adimmune Corp., the only cGMP (current Good Manufacturing Practices) human-vaccine maker in Taiwan, recently claimed that it will begin exporting human vaccines this year and tap the European Union (EU) market in partnership with Netherlands-based biotechnology company Crucell N.V.

Adimmune estimates that its exports will account for about 10% of revenue this year, but are expected to rise to more than 70% in three to five years.

The Taiwanese vaccine maker is capitalized at NT$1.64 billion (US$54.6 million), and its major products include vaccines for influenzas (accounting about 70% of the firm`s overall revenue), Japanese encephalitis (20%), and tetanus (10%).

Adimmune registered revenue of NT$840 million (US$28 million) in 2010, or pretax earnings of NT$225 million (US$7.5 million) and pretax earnings per share (EPS) of NT$1.37 (US$0.05).

COMPANY STEVE CHAN SAID THAT HIS COMPANY HAD SIGNED A SEVEN-YEAR AGREEMENT WITH CRUCELL TO SUPPLY THE ORIGINAL AGENT TO THE NETHERLANDS-BASED PARTNER, ADDING THAT HE ALSO HOPES ADIMUNNE CAN DIVERSIFY ITS LINE TO INCLUDE VACCINES.

ACCORDING TO CHAN, CRUCELL OWNS THE LICENSES FOR VENDING INFLUENZA DRUGS IN 45 NATIONS, SO IS A GOOD PARTNER TO EXPAND ADIMMUNE`S GLOBAL SALES. ADIMMUNE`S INFLUENZA VACCINE IS APPLYING FOR NEW-DRUG LICENSES TO SWISS AND EU, AFTER COMPLETED CLINICAL TESTS IN SWISS.

Chan claimed that several new vaccines are under development at Adimmune, including that for bird flu (H5N1 virus), intestine virus (EV71) etc. The bird-flu vaccine is fully homegrown, which can only be made in 30 plants in 18 nations.
news.cens.com/cens/html/en/news/news_...

[verwijderd] 3 april 2011 00:27

een goed bericht, maar voor ons te laat...

heb nog steeds geen echte vervanger voor crucell gevonden..
wel wat gestopt in galapagos en morphosys rest buiten de biotech.

wilb52 6 april 2011 14:41

Sinds 2005 was Crucell een slechte investering, zeker in het licht van de verwachtingen die gewekt zijn in al die jaren.
Het beste was geweest , in retrospect, afscheid te nemen in 2005 , en dan zou je porto met een faktor 10 gestegen zijn.
Want sinds ik afscheid heb genomen is mijn porto in minder dan 1 jaar met vele honderden procenten gestegen.
Dus 5 jaar zou zeker 1000% geworden zijn.
Niet in de Biotech, maar in vele andere aandelen die je geen worst voorhouden.
Voor mij nooit geen AVA meer en nooit geen Biotech.
Het liedje : ik ben belazerd is hierop van toepassing van onze Limburger
uit de oude doos.Wim Sonneveld voor de nietwetenden
Nooit geen AVA meer, met 1 uitzondering:
Als mijn investering ( nu 10 keer over de kop)
naar 100 keer over de kop gaat. (:->)
Maar ik zal nooit vergeten :
Geen woorden maar daden.

josti5 8 april 2011 12:28

AVA kan voortaan beter AVM heten: Algemene Vergadering van Misleidenen.

Ook sterkte met het verwerken van deze ervaring, wilb; ikzelf ben nog slechts een beetje in de rouwfase; verder gaat het wel weer...

flosz 11 april 2011 12:02

Graphic on the vaccine market graphics.thomsonreuters.com/F/09/US_V...

Nederlandse beleggers kunnen maandag voor het laatst handelen in aandelen Crucell. Het biotechnologiebedrijf is ingelijfd door het Amerikaanse Johnson & Johnson en verdwijnt van de Nederlandse beurs. www.businesscompleet.nl/kennisbank/Ko...

www.youtube.com/watch?v=TqhOVY58zIo

Fijne kerst…….

[verwijderd] 11 april 2011 16:21

Lijkt meer op een treurige oudejaarsavond...

aossa 12 april 2011 16:05

Al bij al toch een mooie pensioenuitkering op de bank dank zij de crucellen... maar wat ermee aan te vangen, IceSave indachtig ?

NB. GS waarschuwt voor grondstoffen dip!
Weet je wat, ik stop het gewoon in een roze plastic spaarvarkentje omwikkeld in geölied bruin papier en onder de grond ermee!

[verwijderd] 12 april 2011 22:27

En dan niet meer weten, waar je dat gat in de bodem hebt gegraven.
Over 20 eeuwen komt iemand dat spulletje tegen en vraagt zich af wat voor zootje ongeregeld dat is. Zou die uitgestorven soort iets van ruilhandelondersteuning gedaan hebben?

aossa 13 april 2011 13:41

Hou de coördinaten bij via GPS ;-)
En via testament maak ik er een spelletje 'vossenjacht' van...

flosz 28 april 2011 19:35

Weldon: in 2010 JNJ invested nearly $7 billion in R&D #JNJASM, $JNJ
twitter.com/#!/JNJComm

Here we go - Q&A at J&J's Annual Shareholder Meeting. Weldon asking people to not ask Q's about anything important. #JNJASM #JNJ
twitter.com/#!/PharmAid

flosz 2 mei 2011 14:11

Now available: Crucell's Corporate Brochure
Monday, May 2nd 2011
tinyurl.com/6g5crxo

Btw: UK nationals overseas urged to be vigilant and monitor media, OBL. ow.ly/4KZZE

flosz 3 mei 2011 09:50

...a Crucell vaccine was given to 190 individuals every minute during 2010....

www.youtube.com/watch?v=fULgsiJs5TA

[verwijderd] 4 mei 2011 12:56

Ja Flosz,

Wrijf het er nog maar eens in. Gisteren bij AMT op de AVA geweest. Maar een heel klein clubje en zeer bescheiden presentaties. Dat biedt mogelijk meer perspectief voor de toekomst.

YinX was er ook en we hebben samen nog maar eens bevestigd dat we ons genaaid voelen door Crucell.

Op 19 mei Company visit bij AMT vanaf 15.30 - 18.00 (meer nieuws volgt)

Gr

Frank

flosz 5 mei 2011 13:50

quote:
Frenky_Tornado schreef:
Wrijf het er nog maar eens in.

Bioceros Announces Expansion of the Research License Agreement with Crucell on STAR® Technology

Utrecht, The Netherlands, 2 May 2011 – Bioceros B.V. today announced the extension of
the non-exclusive STAR® research license agreement with Crucell. The license agreement
with the Netherlands based company Bioceros covers the production of monoclonal
antibodies. In addition, the extension of the agreement now includes the right for Bioceros
B.V. to sub-license and independently market the STAR® technology to third parties.
Financial details of the agreement were not disclosed.
Bioceros’ CEO Dr. Bram Bout comments: “We are proud to add the STAR® technology to our
service portfolio, building an even stronger and solid service business for pre-clinical
development of biopharmaceutical proteins. The STAR® technology protocols that were
developed at the Bioceros facilities on our CHO platforms add significant value to cell line
generation procedures as we know it. We also value the continuous confidence that Crucell
expresses in the service quality Bioceros delivers by granting Bioceros the right to outlicense
the STAR® technology to potential partners of Bioceros.”
tinyurl.com/3ngvk9k

[verwijderd] 6 mei 2011 09:36

Ja, ja, nu werkt het ineens wel weer prachtig ;(

Groeten,

Frank

flosz 6 mei 2011 19:01

quote:
Frenky_Tornado schreef:
Op 19 mei Company visit bij AMT vanaf 15.30 - 18.00 (meer nieuws volgt)

May 19: Company Visit to AMT
May 6, 2011
Uitnodiging company visit AMT

Graag nodigen wij u uit voor onze company visit op 19 mei a.s. van 15:30 – 18:00 uur bij AMT aan de Meibergdreef 61 te Amsterdam.

Tijdens deze middag zullen Jörn Aldag (CEO), Piers Morgan (CFO) en Dr. Harald Petry (Director Research) een korte presentatie geven. Aansluitend op deze presentaties volgt een rondleiding door het gebouw van AMT en is er nog ruime gelegenheid om elkaar te spreken tijdens een borrel.

U kunt zich voor deze middag aanmelden door een e-mail te sturen naar f.vaneerdenburg@amtbiopharma.com.

Er zijn voor deze middag maximaal 30 plaatsen beschikbaar. Indien u bij deze meeting aanwezig wilt zijn is het dus noodzakelijk uzelf tijdig in te schrijven.
Voor vragen of meer informatie kunt u contact opnemen met Frank van Eerdenburg via eerder genoemd e-mailadres of telefoonnummer 020 - 556 73 94.
www.amtbiopharma.com/finance/news

Gr.

[verwijderd] 10 mei 2011 10:00

CORRECTIE TELEFOONNUMMER

In de uitnodiging is een verkeerd telefoonnummer gezet. Dit moet zijn 020 - 5667394

Sorry voor het ongemak

flosz 12 mei 2011 10:19

June relaunch for national program

Pentavalent Vaccine 12 May, 2011 - The pentavalent vaccine, suspended 18 months ago after five cases of serious ‘adverse effect following immunisation’ (AEFI) or deaths were reported, will be reintroduced next month into the national vaccination programme.

Relying on the findings by experts from the World Health Organisation and laboratory tests, public health officials said it was “unlikely” that the five in one vaccine caused the deaths of the nine babies, who had received the vaccine, when it was launched nationwide in October 2009.
The vaccine is a combination of vaccines against diphtheria, whooping cough (pertussis), tetanus, hepatitis-B and the haemophilus influenza type B (Hib) germ. It’s given to babies in three doses, when they are six, ten and 14 weeks old.
“The deaths were coincidental and, especially in Bhutan, which has an immunisation coverage above 95 percent, any child that falls sick or dies would have had received one vaccine or the other,” public health director, Dr Ugen Dophu said at a press briefing yesterday in Thimphu. A media guide on the vaccine was launched and distributed yesterday.
According to health officials 17 hospitals across the country reported two encephalitis, three convulsions, seven meningitis deaths and another seven sudden deaths after the vaccine was suspended. “This indicates that there were deaths even among children, who did not receive the pentavalent vaccine,” the media guide states. There were about 40 cases of encephalitis cases reported last year in children below a year.
Given the various causes of meningo-encephalitis, such as bacterial, fungal, viral, chemical and because its associated with other diseases, Dr Ugen Dophu said the ministry cannot guarantee that similar “coincidental deaths” will not occur again.
“What we can say is that if we don’t introduce the haemophilus influenza type B (Hib) vaccine into our vaccination program, more than 200 children will continue to die from pneumonia or meningo-encephalitis,” the public health director said. “That’s the rationale to reintroduce the vaccine.” While the vaccine would not eliminate totally the number of children suffering from meningo-encephalitis, it would reduce it, he said.
“We can also guarantee the vaccine we bring from the factory to the outreach clinic is brought at the temperature of 2-8 degrees centigrade, and that this would be maintained until it’s injected into our children,” he said.
The ministry also guarantees that its health workers would give the vaccine properly and also monitor all children who are given the vaccine. “If the AEFIs reported are due to the vaccine, we’ll accept because it’s about our credibility,” the public health director said.
Chief program officer with the public health department Tandin Dorji said data collected between 2006-10 from the region showed that the cases of encephalitis peaked between June and October.
“At the time when Bhutan had introduced the vaccine, the whole of south east Asia region was seeing an outbreak of meningo-encephalitis,” he said. “The cases Bhutan had in 2009 suggest a low level of the disease’s outbreak.”
The ministry is planning to reintroduce the vaccine on June 11 and is now waiting for the vaccines to reach Bhutan by May 23. Manufactured in South Korea, the vaccine, with a trade name Quinvazem, is produced by Crucell and Novartis companies. An Indian company called Panacea Biotec ltd in New Delhi manufactured the previous vaccine.
The ministry is a year into studying the burden of meningo-encephalitis. “It’s a complicated disease, where the cerebro spinal fluid needs to be tested to determine the real cause,” Dr Ugen Dophu said. “If that is found, it can be treated but some deaths do occur.”
tinyurl.com/6xqxhg5

flosz 26 mei 2011 20:06

Pharmaceuticals Business Review :
Infectious Diseases and Vaccines

PLANNED FILINGS 2011-2015

FlumAb

Rabies Antibody

FluCell

tinyurl.com/3uchrl8

www.investor.jnj.com/webcasts-present...

J&J plans to submit some experimental vaccines for approval. tinyurl.com/3lbuzhz

84 Posts, Pagina: 1 2 3 4 5 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 860,01 -5,35 -0,62% 18:05


Germany40^	17.724,10	-0,64%
BEL 20	3.827,75	+0,03%
Europe50^	4.914,94	-0,44%
US30^	37.924,96	-0,23%
Nasd100^	17.243,34	-1,74%
US500^	4.995,45	-1,07%
Japan225^	37.415,98	-1,54%
Gold spot	2.392,13	+0,54%
EUR/USD	1,0654	+0,10%
WTI	82,28	+0,24%